MediciNova achieves enrollment in COMBAT-ALS clinical trial

MediciNova (MNOV) announces that it successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166, or ibudilast. MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis. Dr. Yuichi Iwaki, CEO, commented, “This milestone marks a significant step forward in the development of MN-166, reflecting strong collaboration among clinical sites, investigators, and patient communities. We are grateful to all the patients, their family, caregivers, investigators, and study teams whose dedication made this achievement possible. Reaching our target number enrollment allows us to move confidently into the next phase of the trial and brings us closer to understanding the potential impact of MN-166 and potentially bring hope to the millions of people who suffer from this devastating condition.”